Mirati Therapeutics (MRTX) Tops Q3 EPS by $1.24; Reports Cash and Cash Equivalents of $1.2B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Mirati Therapeutics (MRTX) Tops Q3 EPS by $1.24; Reports Cash and Cash Equivalents of $1.2B
November 9, 2021 4:24 PM EST
Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions,... More
November 9, 2021 7:13 AM EST
Stifel analyst Ben Burnett raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $235.00 (from $202.00) while maintaining a Buy rating.
The analyst commented, "Were reiterating our Buy-rating following initial pembro+adagrasib frontline NSCLC data disclosed in conjunction with the company's 3Q21 update. The... More
